GMJSPic

Just to expand on why I said $IBRX — if this platform actually scales, a lot of people are going to look back in 2036 and wish they paid attention earlier. Here’s why it could be that kind of setup: Yeah, this is the one that actually makes sense when you look at it straight. ANKTIVA is already commercial with those ~99% gross margins and the big YoY ramp. That’s not a science project. It’s authorized in 34+ countries, Macau is live in Asia, and they’re still pushing into places like Korea and Japan with local partners. First-line bladder trial just locked the database. They also locked up exclusive U.S. rights to the Tokyo BCG strain — the SWOG S1602 Phase III trial showed it was non-inferior to TICE BCG, which matters because the BCG shortage has been the real bottleneck limiting the market. In BCG-unresponsive bladder cancer it’s already differentiated. ANKTIVA + BCG has shown 62–71% complete response rates with responses lasting beyond 53 months and ~84% cystectomy avoidance at 3 years. That’s ahead of Keytruda (~41% CR) and Adstiladrin (~51% CR). CG Oncology’s oncolytic virus has reported higher early CR numbers but is still in trials. J&J’s TAR-200 is emerging with local chemo delivery. ANKTIVA is the only approved IL-15 superagonist — it activates NK + T cells and promotes memory formation rather than just blocking a checkpoint or delivering local therapy. IL-15 is a natural signal the body uses to activate natural killer cells and T cells and help form memory cells. A superagonist is an engineered version that delivers a stronger, longer-lasting signal. That mechanism is not limited to the bladder. The bigger point is lymphocyte rescue — restoring a weakened immune system so it can fight disease again. Lymphopenia has an ICD-10 code now and is billable. They’re going after sepsis, HIV, lung, and the lymphocyte rescue angle in general. These aren’t small markets. Sepsis: 166 million cases and 21 million deaths in a single year (Lancet 2021 data). HIV: about 41 million people living with it worldwide. Long COVID: estimates run into the hundreds of millions of people who have had it. Even if only a subset with persistent lymphopenia is addressable, the patient populations are large enough that commercial scale can happen fast if the data land. If the Phase 2s hit, RMAT lets FDA move faster. RMAT is Regenerative Medicine Advanced Therapy — it gives earlier and more frequent FDA meetings, potential for rolling review, and Priority Review eligibility. It’s narrower than Breakthrough Therapy or Fast Track but more tailored to regenerative medicine products like this, which is why it can actually compress timelines when the early data are strong. Still under $10B with short interest sitting there while the commercial side is early and multi-million-patient indications are opening. No direct competition on the mechanism. Patents past 2035. Jim Yong Kim joining as Vice Chairman isn’t nothing either. If the bladder franchise scales, the first-line label expands, and even one of the bigger indications (sepsis or lymphocyte rescue) starts to land by the early 2030s, this is the kind of platform that can re-rate hard. People who waited on the early commercial stage of other platforms later regretted it. By 2036 the question is whether this ends up looking like a single-product biotech or the backbone of a lymphocyte-rescue franchise. It’s not a one-drug story. That’s the setup people are going to wish they caught earlier. Watch the next earnings. If the sales ramp holds and the first-line data land, a lot of people will start paying attention. Don’t wait until the story is obvious. What’s your take — is the platform angle real, or is this still just a bladder story? $IBRX #ANKTIVA #NMIBC #BladderCancer @DrPatrick @JimYongKimWBG @ImmunityBio @BladderCancerUS $NVDA